Skip to content
Researchers
Search UMMC
Mobile Navigation
UMMC Navigation
⌂
UMMC Home
Education
Academic Affairs
For Prospective Students
For Students
For Residents and Fellows
For Faculty
School of Dentistry
School of Graduate Studies
School of Health Related Professions
School of Medicine
School of Nursing
School of Population Health
UMMC Online
Faculty Directory
Health Care
Health Care Home
All UMMC Services
Children's of Mississippi
Find a Doctor
Find a Location
Pay a Bill
UMMC Pricing
Patient and Visitor Information
Referring Physicians
Research
Research Home
Centers and Institutes
Offices
Resources
Participate in Clinical Trials
About
A-Z Site Index
About Us
Accreditations
History
Jobs at UMMC
Leadership
Mission and Vision
Give
MyChart
Appointments
Researchers
Participants
Participants
How to Participate in Clinical Trials
Become a Participant
Frequently Asked Questions
Clinical Trials
Find a Trial - Clinical Trials Database
Research Resources for Participants
Contact Us
More contact information
Researchers
Researchers
Researchers Home
Researcher Road Map
Study Assessment
Study Start-Up
Study Conduct
Study Closure
Office of Research
Home
Clinical Trials Database
Contact Us
More contact information
Sponsors
Research
Research Offices
Office of Clinical Trials
Researchers
Researcher Road Map
Study Conduct
Participant Management
Participant Management
Researchers Home
Researcher Road Map
Research Study Road Map Home
Study Assessment
Study Assessment Home
Confidential Disclosure Agreement
Protocol Development/Review
Site Qualification
Accrual Feasibility
Recruitment Plan
Logistics
Informed Consent Form Design
Financial Disclosure/Conflicts of Interest
Study Start-Up
Study Start-Up Home
Study Activation
Study Activation Home
Activation of Clinical Trials (ACT) Process
Budget
IRB, IBC, and RSC Review
Clinical Trial/Study Agreement
ClinicalTrials.gov Registration
Study Set-Up
Study Set-Up Home
Study Operations Planning
Data Collection Plan
Regulatory Files
Staff Training and Delegation
Lab
CRTU
Research Billing
Investigational Drug Service
Velos CTMS
Velos FAQs
Site Initiation
Study Conduct
Study Conduct Home
Participant Recruitment
Participant Recruitment Home
Advertising
Recruitment
Screening
Consenting
Participant Management
Participant Management Home
Velos CTMS
Biospecimen Management
Participant Follow-Up
Remuneration/Reimbursement
Research Billing
Maintaining Participant Records
Data Collection
Safety Monitoring
Reconsenting
Monitoring Consent Status
Study Oversight, Maintenance and Reporting
Study Oversight, Maintenance and Reporting Home
Regulatory File Maintenance
IRB Continuing Review
Amendments
Reportable Events
Regulatory Reporting
Data Management
Data Query Resolution
Study Monitoring/Audits
Budget Management
Study Closure
Study Closure Home
Study Close-Out Visit
IRB Closure
Archiving Records
Clinicaltrials.gov Closure
Post-Award Closure
Training
Training Home
Clinical Research Professionals Group
CREW Program
Main Content
Maintaining Participant Records
Definition
Maintaining participant records
includes reviewing and updating documents of individuals who are taking part in the study.
Policies/procedures/guidelines/processes
Sponsors expect the study team to maintain participant records and capture data as described in the research plan and to meet regulatory responsibilities.
UMMC’s Record Retention Policy
, which includes provisions for ownership of data, requires the retention of study records in accordance with regulatory, organizational, and sponsor or grantor requirements, but no less than six years following completion of the research.
The following summarizes a few of the more common regulatory requirements:
OHRP
– research records must be retained for at least three years after the completion of the research
HIPAA
– Research authorizations, or documentation of waivers or alterations of authorization, must be held for a minimum of six years after the authorization or waiver/alterations was last obtained or in effect, whichever is later
FDA
– Drugs (and biologics classified as drugs) - For a period of two years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until two years after the investigation is discontinued and FDA is notified
FDA
– Devices (and biologics classified as devices) - For a period of two years after the latter of the following two dates: The date on which the investigation is terminated or completed, or the date that the records are no longer required for purposes of supporting a pre-market approval application or a notice of completion of a product development protocol.